Lundbeck

The study will combine cognitive assessments with genetic data and survey responses to gain insights into the causes of these two mental health conditions.

Dutch gene therapy firm UniQure and academic collaborators have been awarded a three-year grant worth €2.5 million ($3.2 million) from the European Commission to develop a treatment for Huntington’s disease that combines RNAi and gene replacement.

Participating vendors are being asked to build fully functional platforms for next-generation sequence data storage and analysis.

Although Lundbeck's foray into the RNAi drugs scene is modest compared with investments made by other pharmas, it comes at a time when many of those firms have put the brakes on their commitment to the approach.

While a handful of pricey deals have dominated the headlines, a handful of other companies over the past year have formed more modest collaborations to see whether they can take advantage of RNAi as a therapeutic modality.

Lundbeck will use Intomics' data analysis and systems biology expertise and tools to analyze drug development data.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.